Relationship of Endothelin-1, Tumor Necrosis Factor-alpha and Interleukin-6 with the Progression of Heart Failure

Mona Yolanda, Marsetio Donosepoetro, Anwar Santoso

Abstract


BACKGROUNDS: Heart failure, a new epidemic of cardiovascular disease, has become an important issue and its prognosis is poor. Heart failure is the condition where the impaired heart cannot pump enough blood to provide the needs of metabolic tissues and organs. Early diagnosis of heart failure is really crucial to determine the success of treatment and to prevent further myocardial dysfunction and worsening clinical symptoms. This condition can be worsened by ET-1, which triggers the secretion of IL-6 and TNF-α as pro inflammation factors. In Systolic Heart Failure, systolic function changes are accompanied by changes in diastolic function. Thus, the condition of systolic heart failure is worse than Diastolic Heart Failure. The purpose of this study is to assess the relationship of ET-1 with diastolic and systolic heart failure groups and the relationship of ET-1 with TNF-α and IL-6 as pro inflammation factors.

METHODS: The design of this study was cross-sectional analysis on 62 patients with heart failure, grouped according to the classification of diastolic and systolic heart failure.

RESULTS: A significant positive correlation of ET-1 with diastolic and systolic heart failure was found (p=0.008; r=0.324). A significant positive correlation was also found between ET-1 and IL-6 (p=0.001; r=0.393), but a less significant correlation was noted between ET-1 and TNF-α (p=0.201; r=-0.158).

CONCLUSIONS: ET-1 has the strongest correlation (p=0.033) with prevalence ratio 3.930 and can differentiate between Diastolic and Systolic Heart Failure.

KEYWORDS: Endothelin-1 (ET-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), heart failure


Full Text:

PDF

References


Porth CM. Pathophysiology: Concepts of Altered Health States: Heart Failure and Circulatory Shock. 7th ed. Wisconsin: Lippincott Williams & Wilkins; 2005, NLMID

Mair J. Pathophysiology and Laboratory Medicine, Pathophysiology of Heart Failure. In: Wu AHB, editor. Cardiac Markers. 2nd ed. Totowa New Jersey: Humana Press; 2003. p.351-67, CrossRef.

Rich S, McLaughlin VV. Review: Cardiovascular drugs, endothelin receptor blockers in cardiovascular disease. Circulation. 2003; 108: 2184-90, CrossRef.

Luscher TF, Barton M. Endothelins dan endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000; 102: 2434-40, CrossRef.

Browatzky M, Schmidt J, Kubler W, Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells. Basic Res Cardiol. 2000; 95: 98-105, CrossRef.

Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, et al. Endothelin a receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004; 109: 249-54, CrossRef.

Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem. 2004; 50: 1; 33-50, CrossRef.

Epstein FH, Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med.1998; 339: 321-328, CrossRef.

Kosmala W, Przewlocka-Kosmala M. Plasma levels of TNF-α and interleukin-6 before and after treatment of chronic congestive heart failure. Kardiol Pol. 2001: LIV. Nr 4.

Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the health ABC Study. Circulation. 2003; 108: 2317-22, CrossRef.

Jortani SA, Prabhu SD, Valdes R Jr. Strategies for developing biomarkers of heart failure. Clin Chem. 2004; 50: 2: 265-78, CrossRef.

Konstam MA, DeNofrio D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation. 2004; 109: 143-5, CrossRef.

Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens. 2002; 11: 59-66, CrossRef.

Yang Li L, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation. 2004; 109: 255-61, CrossRef.




DOI: https://doi.org/10.18585/inabj.v1i2.93

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute